MannKind Corporation Common Stock (MNKD)
Stock · NASDAQ · Health Care
$3.05as of 10/16/2026
Price chart
Active signals
MNKD Signal Track Record
How signals performed across all stocks →What MNKD's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 32 | -2.4% | 41% | September 25, 2026 |
| Bollinger Band Breakout | 27 | -1.5% | 44% | August 19, 2026 |
| Bollinger Band Breakdown | 20 | +1.1% | 55% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 17 | -4.8% | 35% | September 8, 2026 |
| Any 20-session window (baseline) | 0.0% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. The company's commercial products include Afrezza, an inhaled insulin used to improve glycem…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 591
- Website
- mannkindcorp.com/
Fundamentals
- 1-day range
- $3$3.2
- Market cap
- $1.24B
- P/E (trailing)
- —
- P/E (forward)
- 25.02
- EPS (trailing)
- $-0.14
- Dividend yield
- —
- Beta
- 1.10
- Avg. volume
- 4.55M
- Dividend pay date
- March 3, 2017
How MannKind Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
MannKind Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- MNKDMannKind Corporation Common Stock$3.04▼ 4.70%Market cap $1.24BP/E —$2.23$6.51
- ETONEton Pharmaceuticals Inc. Common Stock$50.31▼ 1.99%Market cap $1.26BP/E 133.39$14.27$66.37
- XERSXeris Biopharma Holdings Inc. Common Stock$10.31▲ 2.38%Market cap $1.27BP/E —$5.25$11.33
- ARDXArdelyx Inc. Common Stock$3.09▼ 5.50%Market cap $1.20BP/E —$3.06$8.4
- AKTSAktis Oncology Inc. Common stock$15.06▼ 5.93%Market cap $1.30BP/E —$14.72$34.19
- SVRASavara Inc. Common Stock$4.45▼ 6.12%Market cap $1.19BP/E —$3.38$7.01
- WVEWave Life Sciences Ltd. Ordinary Shares$3.13▼ 1.88%Market cap $1.19BP/E —$3.56$21.73
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MNKD MannKind Corporation Common Stock | $1.24B | — | $3.04 | ▼ 4.70% | $2.23$6.51 |
| ETON Eton Pharmaceuticals Inc. Common Stock | $1.26B | 133.39 | $50.31 | ▼ 1.99% | $14.27$66.37 |
| XERS Xeris Biopharma Holdings Inc. Common Stock | $1.27B | — | $10.31 | ▲ 2.38% | $5.25$11.33 |
| ARDX Ardelyx Inc. Common Stock | $1.20B | — | $3.09 | ▼ 5.50% | $3.06$8.4 |
| AKTS Aktis Oncology Inc. Common stock | $1.30B | — | $15.06 | ▼ 5.93% | $14.72$34.19 |
| SVRA Savara Inc. Common Stock | $1.19B | — | $4.45 | ▼ 6.12% | $3.38$7.01 |
| WVE Wave Life Sciences Ltd. Ordinary Shares | $1.19B | — | $3.13 | ▼ 1.88% | $3.56$21.73 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Reported Friday, MannKind’s Under-10-Second Furoscix ReadyFlow Autoinjector Shows Urine Output Comparable To IV Furosemide In New HFSA 2026 Analyses, Supporting Outpatient Edema Management In Heart Failure And CKDbenzinga · 10/12/2026
- MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)Yahoo · 10/10/2026
- Truist Securities Maintains Buy on MannKind, Lowers Price Target to $5Benzinga · 10/7/2026
- United Therapeutics: The Market Sees The Erosion, Not The Refill - BuySeekingAlpha · 9/27/2026
- MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains MomentumYahoo · 9/17/2026
- MannKind (MNKD) Bets On Inhaled Weight Loss Amid Widening LossesYahoo · 9/16/2026
Insider Activity
Insider Actions →- Steven B. Binder · September 25, 2026 · Sale39.1K @ $3.29
- Steven B. Binder · September 10, 2026 · Sale33.6K @ $3.81
- Steven B. Binder · August 7, 2026 · Sale39.1K @ $4.06
- Steven B. Binder · July 17, 2026 · Sale52.5K @ $4.06
- David Thomson · July 17, 2026 · Sale24.1K @ $4.05
- Michael Castagna · July 15, 2026 · Tax Withholding58.9K @ $4.09
- Steven B. Binder · July 15, 2026 · Tax Withholding4.6K @ $4.09
- Steven B. Binder · July 15, 2026 · Tax Withholding4.1K @ $4.09
- Steven B. Binder · July 15, 2026 · Tax Withholding15.7K @ $4.09
- Michael Castagna · July 15, 2026 · Option Exercise350.3K
- Stuart A. Tross · July 15, 2026 · Tax Withholding33.7K @ $4.09
- David Thomson · July 15, 2026 · Option Exercise93.8K
- David Thomson · July 15, 2026 · Tax Withholding16.4K @ $4.09
- David Thomson · July 15, 2026 · Tax Withholding17.8K @ $4.09
- David Thomson · July 15, 2026 · Tax Withholding12.7K @ $4.09
Institutional Ownership
March 31, 2026
- Total shares held
- 177.01M
- Total value held
- $432.04M
- Institutional holders
- 243
- Unknown28.60M
- Unknown18.68M
- Unknown12.89M
- Unknown8.26M
- Unknown7.51M
- Unknown6.39M
- Unknown5.90M
- Unknown5.79M
- Unknown4.95M
- Unknown4.29M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
MannKind Presents Furoscix Data at HFSA 2026
MannKind reported new data at the HFSA 2026 conference showing that its Furoscix ReadyFlow autoinjector produced urine output comparable to IV furosemide. The study supports the use of the device for managing edema in patients with heart failure and chronic kidney disease. Truist Securities maintained its rating on the stock but lowered its price target to $5.
MannKind Presents Furoscix Data at HFSA 2026. MannKind reported new data at the HFSA 2026 conference showing that its Furoscix ReadyFlow autoinjector produced urine output comparable to IV furosemide. The study supports the use of the device for managing edema in patients with heart failure and chronic kidney disease. Truist Securities maintained its rating on the stock but lowered its price target to $5.